- Home
- CDLR vs OCS Comparison
CDLR vs OCS Comparison
Compare CDLR & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CDLR | OCS |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | | |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CDLR | OCS |
|---|---|---|
| Price | $26.23 | $28.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $39.57 |
| AVG Volume (30 Days) | 133.4K | ★ 333.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $144.16 | $14.53 |
| Revenue Next Year | $69.44 | $691.13 |
| P/E Ratio | $7.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.37 | $14.00 |
| 52 Week High | $26.35 | $29.36 |
Technical Indicators
Market Signals| Indicator | CDLR | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 72.96 | 66.31 |
| Support Level | $25.58 | $27.30 |
| Resistance Level | $26.35 | $29.10 |
| Average True Range (ATR) | 0.61 | 1.20 |
| MACD | 0.08 | -0.17 |
| Stochastic Oscillator | 94.89 | 80.12 |
Price Performance
Historical ComparisonAbout CDLR Cadeler AS
Cadeler AS is an offshore wind farm vessel contractor. It is engaged in offshore wind farm construction, maintenance, and decommissioning and provides marine and engineering operations to the wind industry, focusing on safety and the environment. The company operates six offshore jack-up wind farm installation vessels. In addition to wind farm installation, these vessels can perform maintenance, construction, decommissioning, and other tasks within the offshore industry.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.